Safety Evaluation
Early safety evaluation of lead compounds is an indispensable core checkpoint in the full lifecycle of innovative drug research and development. Unidentified cytotoxicity, genetic toxicity or potential cardiotoxicity hidden in lead molecules will lead to severe clinical adverse reactions, high preclinical trial failure rates and massive waste of R&D capital costs. As a reliable professional CRO brand under STEMart, PharmaAnalytica provides dedicated one-stop in vitro Safety Evaluation services tailored for lead compound optimization stages. We are equipped with a full set of self-operated, high-standard supporting hardware platforms, including intelligent cell culture incubators, sterile biosafety cabinets, multi-functional full-wavelength microplate readers, high-resolution cell imaging analysis systems, dedicated microbial constant temperature culture equipment and professional electrophysiological testing workstations. Relying on standardized SOP management and full-process quality control, we deliver comprehensive, accurate and regulatory-compliant compound toxicity profiling data, helping pharmaceutical enterprises eliminate high-risk lead molecules in advance, optimize compound structural design, and effectively reduce subsequent in vivo trial risks and overall R&D cycle pressure.
Specialized Safety Evaluation Services
Cytotoxicity Assay
Our in vitro cytotoxicity assays serve as the first-tier rapid toxicity screening tool for batch lead compound prioritization in early drug development. Using professional sterile cell culture platforms and high-sensitivity multi-mode microplate readers, we culture normal human-derived cell lines and key functional tissue cells in vitro, then incubate them with lead compounds at gradient concentration levels. Through colorimetric and fluorescence quantitative detection technologies, we accurately detect cell viability, proliferation inhibition and morphological damage changes after compound intervention. The whole testing process follows unified in vitro toxicology guidelines, quantitatively evaluating the acute cytotoxic potential and safe exposure dose range of candidate molecules. It efficiently screens out compounds with strong universal cellular toxicity, providing reliable preliminary safety data for subsequent advanced genetic toxicity and cardiotoxicity testing arrangements.
Ames Test
The Ames bacterial reverse mutation test is a mandatory in vitro genetic toxicity detection item for all lead compounds before entering formal preclinical research. We deploy standard Salmonella typhimurium and Escherichia coli test strains, matched with professional microbial constant-temperature anaerobic and aerobic integrated culture systems. We set up both metabolic activation and non-activation experimental groups to simulate complex in vivo metabolic microenvironments of human liver enzymes. By observing the reverse mutation colony growth status of bacteria induced by lead compounds, we scientifically judge whether the test molecule has potential DNA damage and gene mutagenic activity. The test fully complies with global pharmacopeia and OECD guiding principles, effectively warning genetic mutation risks and avoiding irreversible hereditary safety hazards of candidate drugs in clinical application.
In Vitro Micronucleus Test
The in vitro micronucleus test is used to comprehensively evaluate the chromosome damage toxicity risk of lead compounds, complementing the genetic toxicity assessment system of the Ames test. We adopt mammalian cultured cell lines, strictly carry out synchronous cell culture and compound intervention treatment in a GMP-grade cell experimental room. Supported by high-resolution automatic cell imaging and intelligent analysis equipment, we fix, stain and microscopically scan mass cell samples in batches. We statistically count the micronucleus formation rate in binucleated cells, accurately judging whether the compound induces chromosome fracture or chromosome nondisjunction abnormalities. This high-sensitivity testing method captures potential chromosomal genotoxicity that is difficult to identify by single bacterial testing, realizing full-coverage genetic safety risk control of lead compounds.
hERG Channel Assay
The hERG channel assay is the core key item to evaluate the cardiotoxicity risk of lead compounds and prevent clinical QT interval prolongation and sudden cardiac death accidents. We use stable hERG gene-transfected cell lines, supported by professional high-precision electrophysiological detection workstations. We record real-time potassium current changes of cardiomyocyte hERG channels before and after lead compound administration through patch-clamp technology. By analyzing the current inhibition degree and dose-response relationship, we quantitatively evaluate the blocking effect of the compound on cardiac ion channels. The data directly judges the potential proarrhythmia risk of the molecule, effectively blocking lead compounds with hidden cardiac safety hazards from entering expensive in vivo pharmacodynamic and pharmacokinetic trials.
Why Choose PharmaAnalytica?
Professional Toxicology Expert Team
Our technical team consists of senior in vitro pharmacologists and toxicology specialists, who are fully familiar with OECD and ICH safety evaluation guidelines. With rich practical experience in lead compound rapid screening, they can flexibly cope with special structural compound detection difficulties and ensure scientific and rigorous experimental design.
Full-Set Safety Detection Hardware Platform
The laboratory is fully equipped with complete cell culture, microbial culture and high-end analytical testing instruments, all operated independently in-house. No external outsourcing is involved, ensuring stable experimental repeatability, controllable testing cycles and zero risk of data leakage for all toxicity projects.
One-Stop Toxicity Evaluation System
We integrate cytotoxicity, genetic toxicity and cardiac safety testing to build a closed-loop early safety evaluation system. It fully meets the full-range safety screening needs of lead compounds from primary batch screening to candidate molecule confirmation, greatly simplifying enterprise R&D docking procedures.
Compliant Raw Data and Customized R&D Solutions
All tests retain complete original imaging data and experimental records with full audit trails. We issue English standardized reports directly used for project review and preclinical filing. Meanwhile, we provide accelerated testing schedules to match clients' urgent compound optimization progress.
Overall, backed by STEMart's strong resource strength and standardized laboratory management, PharmaAnalytica delivers high-precision, time-saving and fully compliant lead compound safety evaluation services. We effectively help global pharmaceutical enterprises control early safety risks, optimize molecular structures, and steadily accelerate the efficient layout of innovative drug R&D pipelines.
Online Inquiry
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Need More Information or Request A Quotation?
Related Links
